Please wait while we load the requested 10-K report or click the link below:
Alexion Pharmaceuticals, Inc.
Sr. Director, Corporate Communications
Makovksy + Company (Media)
Rx Communications (Investors)
Alexion Reports Fourth Quarter and Full Year 2010 Results
- Soliris® Net Product Sales Increased 40 Percent to $541 Million in 2010
- Continued Strong Uptake of Soliris by New Patients in Core Territories: U.S., Western Europe and Japan
- aHUS and Transplant Programs Advance
- Taligen and Orphatec Acquisitions Expand Rare Disease Pipeline -
Fourth Quarter 2010 Financial Highlights:
Q4 2010 net product sales increased 41 percent to $156.0 million, compared to $110.6 million in Q4 2009.
Q4 2010 GAAP net income was $26.5 million, or $0.28 per share, compared to Q4 2009 GAAP net income of $237.1 million, or $2.59 per share, which included a non-recurring tax benefit of $215.5 million, or $2.36 per share.
Q4 2010 non-GAAP net income increased 71 percent to $48.6 million, or $0.51 per share, compared to Q4 2009 non-GAAP net income of $28.5 million, or $0.31 per share.
Full-Year 2010 Financial Highlights:
2010 net product sales increased 40 percent to $541.0 million, compared to $386.8 million in 2009.
2010 GAAP net income was $97.0 million, or $1.04 per share, compared to 2009 GAAP net income of $295.2 million, or $3.26 per share, which included a non-recurring tax benefit of $215.5 million, or $2.38 per share.
2010 non-GAAP net income increased 54 percent to $167.3 million, or $1.78 per share, compared to 2009 non-GAAP net income of $108.4 million, or $1.18 per share.
CHESHIRE, Conn., February 10, 2011 Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the quarter and year ended December 31, 2010. For the three
The following information was filed by Alexion Pharmaceuticals, Inc. (ALXN) on Thursday, February 10, 2011 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Alexion Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Alexion Pharmaceuticals, Inc..